SI
AXSM icon

Sofinnova Investments’s Axsome Therapeutics AXSM Stock Holding History

Sofinnova Investments’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-100,000
Closed -$8.46M – 69
2024
Q4 		$8.46M Buy
+100,000
New +$9.2M 0.62% 36

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sofinnova Investments's AXSM Position: Q2 2026 in Review

Sofinnova Investments reduced its Axsome Therapeutics (AXSM) stake by 25% in Q2 2026, selling an estimated $11.3M and leaving 160,429 shares worth $39.3M. The position accounts for 2.03% of the portfolio, ranked #16.

Sofinnova Investments first reported a position in AXSM in Q1 2020 and has held it in 14 quarters since. The position peaked at $47.8M in Q3 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Sofinnova Investments held 160,429 shares of Axsome Therapeutics worth $39.3M as of Q2 2026.
  • Sofinnova Investments sold 52,318 Axsome Therapeutics shares in Q2 2026, an estimated $11.3M.
  • Axsome Therapeutics made up 2.03% of Sofinnova Investments's portfolio in Q2 2026, its #16 holding.
  • Sofinnova Investments first reported a position in Axsome Therapeutics in Q1 2020 and has held it in 14 quarters since.
  • Sofinnova Investments's Axsome Therapeutics position peaked at $47.8M in Q3 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.